Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTERoiD: Six Weeks of Daily Rifapentine vs. 12-16 Week Rifamycin-based Treatment of Latent Tuberculosis
NCT03474029Phase 3Recruiting
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Aug 2019
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of rifapentine in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Started Aug 2019; status: recruiting.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03474029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474029.